<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mrj</journal-id><journal-title-group><journal-title xml:lang="ru">Современная ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Modern Rheumatology Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1996-7012</issn><issn pub-type="epub">2310-158X</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1996-7012-2021-6-72-75</article-id><article-id custom-type="elpub" pub-id-type="custom">mrj-1230</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL INVESTIGATIONS</subject></subj-group></article-categories><title-group><article-title>Сывороточный амилоид А как маркер активности анкилозирующего спондилита</article-title><trans-title-group xml:lang="en"><trans-title>Serum amyloid A as a marker of ankylosing spondylitis activity</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2486-8798</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сахарова</surname><given-names>К. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Sakharova</surname><given-names>K. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe shosse, Moscow 115522</p></bio><email xlink:type="simple">marsupilami563@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3246-1157</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Черкасова</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Cherkasova</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe shosse, Moscow 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3195-5187</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Эрдес</surname><given-names>Ш. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Erdes</surname><given-names>Sh. F.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe shosse, Moscow 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>15</day><month>12</month><year>2021</year></pub-date><volume>15</volume><issue>6</issue><fpage>72</fpage><lpage>75</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Сахарова К.В., Черкасова М.В., Эрдес Ш.Ф., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Сахарова К.В., Черкасова М.В., Эрдес Ш.Ф.</copyright-holder><copyright-holder xml:lang="en">Sakharova K.V., Cherkasova M.V., Erdes S.F.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://mrj.ima-press.net/mrj/article/view/1230">https://mrj.ima-press.net/mrj/article/view/1230</self-uri><abstract><p>Сывороточный амилоидный белок А (SАА) является нормальным белком сыворотки крови (служит предшественником фибриллярного тканевого белка АА), синтезируемым в печени, и быстро реагирующим маркером острой фазы воспаления. Постоянная высокая концентрация SAA – один из факторов развития АА-амилоидоза. Как правило, вторичный амилоидоз развивается у пациентов с длительно текущими и плохо контролируемыми воспалительными заболеваниями, в том числе ревматическими, одним из которых является анкилозирующий спондилит (АС).</p><p>Цель исследования – определение уровня SAA при АС и его взаимосвязи с показателями активности болезни.</p><sec><title>Пациенты и методы</title><p>Пациенты и методы. В исследование включено 124 пациента с АС, соответствовавших модифицированным Нью-Йорским критериям 1984 г. Активность заболевания и функциональный статус пациентов оценивались согласно рекомендациям российских экспертов. Всем пациентам проводили определение SAA и СРБ, СОЭ в сыворотке крови.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. Медиана концентрации SAA составляла 12,5 мг/л [4; 71,6]. Из 124 пациентов у 31% уровень SAA был &lt;5 мг/л, а у 69 % – &gt;5 мг/л. Выявлена сильная связь между уровнями SAA и СРБ (r=0,80, p&lt;0,000001), значимой связи между SAA и СОЭ не обнаружено (r=0,31, p=0,92). Корреляция между активностью АС по индексу BASDAI и SAA была слабой (r=0,3, p&lt;0,002), а с ASDAS-СРБ – умеренной (r=0,54, p&lt;0,00001).</p></sec><sec><title>Заключение</title><p>Заключение. Выявлена статистически значимая связь между уровнями SAA и СРБ, а также индексами активности АС. Исследование показало, что SAA может использоваться в качестве одного из маркеров воспаления при АС.</p></sec></abstract><trans-abstract xml:lang="en"><p>Serum amyloid A protein A (SAA) is a normal serum protein (serving as a precursor of fibrillar tissue protein AA), synthesized in the liver and a rapidly responding marker of the acute phase of inflammation. A constant high concentration of SAA is one of the factors in the development of AA-amyloidosis. As a rule, secondary amyloidosis develops in patients with long-term and poorly controlled inflammatory diseases, including rheumatic diseases, one of which is ankylosing spondylitis (AS).</p><sec><title>Objective</title><p>Objective: to assess the level of SAA in AS patients and its relationship with indicators of disease activity.</p></sec><sec><title>Patients and methods</title><p>Patients and methods. The study included 124 patients with AS who met the modified New York 1984 criteria. The disease activity and functional status of patients were assessed according to the recommendations of Russian experts. SAA and CRP, ESR in blood serum were measured in all patients.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. The median SAA concentration was 12.5 mg/L [4; 71.6]. Of 124 patients, 31% had SAA levels &lt;5 mg/L and 69% had &gt;5 mg/L. A strong correlation was found between the levels of SAA and CRP (r=0.80, p&lt;0.000001), no significant relationship was found between SAA and ESR (r=0.31, p=0.92). The correlation between the AS activity according to the BASDAI index and SAA was weak (r=0.3, p&lt;0.002), the correlation with ASDAS-CRP was moderate (r=0.54, p&lt;0.00001).</p></sec><sec><title>Conclusion</title><p>Conclusion. A statistically significant relationship was found between SAA and CRP levels, as well as the AS activity indices. Research has shown that SAA can be used as one of the markers of inflammation in AS.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>анкилозирующий спондилит</kwd><kwd>HLA-B27</kwd><kwd>SAA</kwd><kwd>СРБ</kwd><kwd>СОЭ</kwd><kwd>вторичный амилоидоз</kwd></kwd-group><kwd-group xml:lang="en"><kwd>ankylosing spondylitis</kwd><kwd>HLA-B27</kwd><kwd>SAA</kwd><kwd>CRP</kwd><kwd>ESR</kwd><kwd>secondary amyloidosis</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование выполнено в рамках поискового научного исследования «Разработка методов терапии рефрактерного тяжелого анкилозирующего спондилита» (ААА-А20-120041390035-8).</funding-statement><funding-statement xml:lang="en">The investigation has been conducted within scientific topic №AAA-A20-120041390035-8 «Development of treatment methods for refractory severe ankylosing spondylitis».</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Лысенко (Козловская) ЛВ, Рамеев ВВ, Моисеев СВ и др. Клинические рекомендации по диагностике и лечению системного амилоидоза. Клиническая фармакология и терапия. 2020;29(1):13-24.</mixed-citation><mixed-citation xml:lang="en">Lysenko (Kozlovskaya) LV, Rameev VV, Moiseev SV, et al. Clinical recommendations for the diagnosis and treatment of systemic amyloidosis. Klinicheskaya farmakologiya i terapiya. 2020;29(1):13-24. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003 Aug 7;349(6):583-96. doi: 10.1056/NEJMra023144.</mixed-citation><mixed-citation xml:lang="en">Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003 Aug 7;349(6):583-96. doi: 10.1056/NEJMra023144.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Pepys MB. Amyloidosis. Annu Rev Med. 2006;57:223-41. doi: 10.1146/annurev.med.57.121304.131243.</mixed-citation><mixed-citation xml:lang="en">Pepys MB. Amyloidosis. Annu Rev Med. 2006;57:223-41. doi: 10.1146/annurev.med.57.121304.131243.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Parmelee DC, Titani K, Ericsson LH, et al. Amino acid sequence of amyloid-related apoprotein (apoSAA1) from human highdensity lipoprotein. Biochemistry. 1982 Jul 6;21(14):3298-303. doi: 10.1021/bi00257a008.</mixed-citation><mixed-citation xml:lang="en">Parmelee DC, Titani K, Ericsson LH, et al. Amino acid sequence of amyloid-related apoprotein (apoSAA1) from human highdensity lipoprotein. Biochemistry. 1982 Jul 6;21(14):3298-303. doi: 10.1021/bi00257a008.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ledue TB, Weiner DL, Sipe JD, et al. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannosebinding protein in human serum. Ann Clin Biochem. 1998 Nov;35 ( Pt 6):745-53. doi: 10.1177/000456329803500607.</mixed-citation><mixed-citation xml:lang="en">Ledue TB, Weiner DL, Sipe JD, et al. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannosebinding protein in human serum. Ann Clin Biochem. 1998 Nov;35 ( Pt 6):745-53. doi: 10.1177/000456329803500607.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Laiho K, Tiitinen S, Kaarela K, et al. Secondary amyloidosis has decreased in patients with inflammatory joint disease in Finland. Clin Rheumatol. 1999;18(2):122-3. doi: 10.1007/s100670050068.</mixed-citation><mixed-citation xml:lang="en">Laiho K, Tiitinen S, Kaarela K, et al. Secondary amyloidosis has decreased in patients with inflammatory joint disease in Finland. Clin Rheumatol. 1999;18(2):122-3. doi: 10.1007/s100670050068.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Singh G, Kumari N, Aggarwal A, et al. Prevalence of subclinical amyloidosis in ankylosing spondylitis. J Rheumatol. 2007 Feb;34(2):371-3.</mixed-citation><mixed-citation xml:lang="en">Singh G, Kumari N, Aggarwal A, et al. Prevalence of subclinical amyloidosis in ankylosing spondylitis. J Rheumatol. 2007 Feb;34(2):371-3.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Муравьев ЮВ, Алексеева АВ. Частота АА-амилоидоза при ревматических заболеваниях (по данным ГУ Института ревматологии РАМН). Научно-практическая ревматология. 2004;42(3):20-2.</mixed-citation><mixed-citation xml:lang="en">Murav'ev YuV, Alekseeva AV. Frequency of AA-amyloidosis in rheumatic diseases (according to the State Institute of Rheumatology of the Russian Academy of Medical Sciences). Nauchno-prakticheskaya revmatologiya. 2004;42(3):20-2. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kobak S, Oksel F, Kabasakal Y, et al. Ankylosing spondylitis-related secondary amyloidosis responded well to etanercept: a report of three patients. Clin Rheumatol. 2007 Dec;26(12):2191-4. doi: 10.1007/s10067-007-0679-x. Epub 2007 Jul 5.</mixed-citation><mixed-citation xml:lang="en">Kobak S, Oksel F, Kabasakal Y, et al. Ankylosing spondylitis-related secondary amyloidosis responded well to etanercept: a report of three patients. Clin Rheumatol. 2007 Dec;26(12):2191-4. doi: 10.1007/s10067-007-0679-x. Epub 2007 Jul 5.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007 Jun 7;356(23):2361-71. doi: 10.1056/NEJMoa070265.</mixed-citation><mixed-citation xml:lang="en">Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007 Jun 7;356(23):2361-71. doi: 10.1056/NEJMoa070265.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Дубинина ТВ, Гайдукова ИЗ, Годзенко АА и др. Рекомендации по оценке активности болезни и функционального состояния больных анкилозирующим спондилитом в клинической практике. Научно-практическая ревматология. 2017; 55(4):344-50.</mixed-citation><mixed-citation xml:lang="en">Dubinina TV, Gaidukova IZ, Godzenko AA, et al. Recommendations for assessing the activity of the disease and the functional state of patients with ankylosing spondylitis in clinical practice. Nauchno-prakticheskaya revmatologiya. 2017;55(4):344-50. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Yung SY, Park MC, Park YB, et al. Serum amyloid a as a useful indicator of disease activity in patients with ankylosing spondylitis. Yonsei Med J. 2007 Apr 30;48(2):218-24. doi: 10.3349/ymj.2007.48.2.218.</mixed-citation><mixed-citation xml:lang="en">Yung SY, Park MC, Park YB, et al. Serum amyloid a as a useful indicator of disease activity in patients with ankylosing spondylitis. Yonsei Med J. 2007 Apr 30;48(2):218-24. doi: 10.3349/ymj.2007.48.2.218.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Hwang YG, Balasubramani GK, Metes ID, et al. Differential response of serum amyloid A to different therapies in early rheumatoid arthritis and its potential value as a disease activity biomarker. Arthritis Res Ther. 2016 May 17;18(1):108. doi: 10.1186/s13075-016-1009-y.</mixed-citation><mixed-citation xml:lang="en">Hwang YG, Balasubramani GK, Metes ID, et al. Differential response of serum amyloid A to different therapies in early rheumatoid arthritis and its potential value as a disease activity biomarker. Arthritis Res Ther. 2016 May 17;18(1):108. doi: 10.1186/s13075-016-1009-y.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">De Vries MK, van Eijk IC, van der HorstBruinsma IE, et al. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum. 2009 Nov 15;61(11):1484-90. doi: 10.1002/art.24838.</mixed-citation><mixed-citation xml:lang="en">De Vries MK, van Eijk IC, van der HorstBruinsma IE, et al. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum. 2009 Nov 15;61(11):1484-90. doi: 10.1002/art.24838.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Eklund KK, Niemi K, Kovanen PT. Immune functions of serum amyloid A. Crit Rev Immunol. 2012;32(4):335-48. doi: 10.1615/critrevimmunol.v32.i4.40.</mixed-citation><mixed-citation xml:lang="en">Eklund KK, Niemi K, Kovanen PT. Immune functions of serum amyloid A. Crit Rev Immunol. 2012;32(4):335-48. doi: 10.1615/critrevimmunol.v32.i4.40.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
